Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIAGEN for Chemotherapy-Induced Peripheral Neuropathy
NCT04112641Phase 2Active, not recruiting
- Sponsor
- Donna Hammond
- Start
- Feb 2020
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing Placebo capsules with Nicotinamide Riboside (NIAGEN) (2 arms). Primary endpoints: Quality of Life Questionnaire Chemotherapy-induced Peripheral Neuropathy Sensory Subscale at 84 days and Quality of Life Questionnaire Chemotherapy-induced Peripheral Neuropathy Motor Subscale at 84 days. Started Feb 2020; status: active, not recruiting.
02
Drugs
nicotinamide riboside
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT04112641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04112641.